ScRNA‐seq has enabled the identification of rare T cell populations with superior anti‐tumor efficacy in the TME, including CXCL13+ T cells, which are increasingly recognized for their responsiveness to ICB.[17, 21] CXCL13, a chemokine primarily interacting with CXCR5, is secreted by T cells and acts on B cells and T cells within the TME,[35, 57] which is consistent with our findings in scRNA‐seq analysis. This evidence concerns the gene CXCR5 and neoplasm.